- Home
- NSLR vs CUE Comparison
NSLR vs CUE Comparison
Compare NSLR & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSLR | CUE |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 180.3M | 177.0M |
| IPO Year | 2011 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NSLR | CUE |
|---|---|---|
| Price | $6.22 | $16.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $15.94 | ★ $88.00 |
| AVG Volume (30 Days) | 295.7K | ★ 388.2K |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | ★ 15.63% | N/A |
| EPS Growth | ★ 211.25 | 61.11 |
| EPS | ★ 4.58 | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.63 | N/A |
| P/E Ratio | $1.40 | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $6.40 | $0.17 |
| 52 Week High | $12.19 | $45.50 |
Technical Indicators
Market Signals| Indicator | NSLR | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 16.48 | 34.10 |
| Support Level | N/A | $0.24 |
| Resistance Level | $8.36 | $33.95 |
| Average True Range (ATR) | 0.29 | 2.72 |
| MACD | -0.04 | -0.91 |
| Stochastic Oscillator | 1.05 | 4.10 |
Price Performance
Historical ComparisonAbout NSLR Neostellar Capital Corp. Common Stock
Neostellar Capital Corp is an investment company focused on private, venture-backed businesses. It invests in companies that are not yet listed on a public stock exchange. It helps investors to gain exposure to a portfolio of VC-backed companies through a publicly traded stock.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.